# FORTITUDE-102 (NCT05111626)

> Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05111626
- Phase: PHASE3
- Status: TERMINATED
- Sponsor: Amgen
- Conditions: Gastric Cancer; Gastroesophageal Junction Adenocarcinoma
- Interventions: Bemarituzumab; Nivolumab; Chemotherapy; Placebo
- Enrollment: 515
- Primary outcome: Part 1: Number of Participants Who Experienced DLTs
- Primary outcome: Part 1: Number of Participants Who Experienced One or More Treatment-Emergent Adverse Events (TEAEs)
- Primary outcome: Part 1: Number of Participants Who Experienced One or More Related TEAEs
- Primary outcome: Part 1: Number of Participants With Clinically Significant Changes in Vital Signs
- Primary outcome: Part 1: Number of Participants With Clinically Significant Changes in Visual Acuity
- Primary outcome: Part 1: Number of Participants With Clinically Significant Changes in Physical Examinations
- Primary outcome: Part 1: Number of Participants with Clinically Significant Changes in Clinical Laboratory Tests
- Primary outcome: Part 2: Overall Survival in FGFR2b ≥ 10% 2+/3+ Tumor Cell Staining Participants

## Commentary we found

- YouTube: 7
- Podcasts: 6
- X threads: 6

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=fortitude-102-nct05111626

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05111626", "email": "<work email>"}; the inbox owner confirms by the emailed link.